Timothy I. Richardson

ARSA generates evidence-based target shortlists for Alzheimer's disease and related dementias by integrating natural language research interests with molecular data and cross-cohort evidence.

This study identifies SHIP1 ligands with brain exposure and in vivo activity in Alzheimer's models, showing target engagement and reduced neuroinflammation.

This paper introduces SLGNN, a sparse learning approach for drug-protein binding prediction that identifies chemically valid key structures with better predictive power than existing methods.

This paper identifies VDAC1 as the target of SW016789, a hypersecretion inducer, and shows it causes distinct transcriptomic changes in beta-cells compared to ER stress.

This study examines the proteomic and transcriptomic effects of SHIP1 modulation in microglia, revealing significant proteomic changes in SHIP1 homozygous knockout and differences between BV2 and HMC3 cell lines.

The paper compiles an annotated set of 171 small molecule modulators targeting 98 novel AD therapeutic proteins, serving as chemical tools for hypothesis validation.